Search Results
Your search for ,wAs matches 27466 pages
Showing 8701 - 8750School-Based HPV Vaccination Program Reduces Rates of HPV in Gay and Bisexual Men
An Australian study published by Chow et al in The Lancet Infectious Diseases found a 70% reduction in one type of human papillomavirus (HPV) in gay and bisexual men after the implementation of the school-based HPV vaccination program. The HYPER2 study found that there was a significant reduction...
AUA Announces Updates to Clinical Guidance for Renal Mass and Localized Renal Cancer
The American Urological Association (AUA) announced amendments to its clinical guideline on Renal Masses and Localized Renal Cancer, originally published in 2013 and updated in 2017, based on an additional literature search conducted through October 2020. One in four renal masses are benign;...
Cemiplimab-rwlc for Patients With Locally Advanced Basal Cell Carcinoma After Hedgehog Inhibitor Therapy
As reported in The Lancet Oncology by Stratigos et al, findings in a subgroup of a phase II trial have shown that the PD-1 antibody cemiplimab-rwlc produces enduring responses in patients with locally advanced basal cell carcinoma who had progressive disease on or intolerance to prior hedgehog...
Use of Systemic Therapy at the End of Life in Patients With Cancer: Effect of Approval of Immunotherapies
In a study reported in JCO Oncology Practice, Khaki et al found that although the use of anticancer systemic therapy during the last 30 days of life in patients with cancer has decreased overall since the first approval of a PD-1 immune checkpoint inhibitor, the use of PD-1 or PD-L1 inhibitors...
Effect of Lower Endoscopy on Colorectal Cancer Incidence and Mortality in Individuals Older Than 75
In a prospective cohort study reported in JAMA Oncology, Ma et al found that lower endoscopy colorectal cancer screening in individuals older than age 75 was associated with reduced colorectal cancer incidence and mortality, although no colorectal cancer mortality benefit was observed in those with ...
Actionable Mutations Identified in Majority of Genome-Sequenced Resected Cholangiocarcinomas
Tumor genomic profiling of resected cholangiocarcinomas may reveal mutations targetable with agents currently being used for other cancers, according to the results of a study presented at the Society of Surgical Oncology (SSO) 2021 International Conference on Surgical Cancer Care.1 Among patients...
ORIENT-12 Study: Addition of Sintilimab to Gemcitabine/Platinum in Advanced Squamous NSCLC
Adding sintilimab to a regimen of gemcitabine and platinum demonstrated clinical benefit over gemcitabine and platinum alone as first-line therapy in patients with locally advanced or metastatic squamous non–small cell lung cancer (NSCLC). These results from the ORIENT-12 trial were published by...
Adjuvant and Concurrent Temozolomide in 1p/19q Non-Codeleted Anaplastic Glioma: Survival Benefit Analysis
In the second interim analysis of the phase III CATNON trial reported in The Lancet Oncology, Martin J. van den Bent, MD, PhD, and colleagues found that adjuvant temozolomide—but not temozolomide concurrent with radiotherapy—was associated with an overall survival benefit in patients with newly...
Perioperative Systemic Therapy for Patients With Resectable Colorectal Peritoneal Metastases
In the phase II portion of a Dutch phase II/III trial (CAIRO6) reported in JAMA Surgery, Rovers et al found that the addition of perioperative systemic therapy to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) was feasible and safe for the treatment of patients with ...
Oncology Hospital-at-Home Program Reduced Unplanned Health-Care Utilization and Costs
In the Huntsman at Home Real-World Trial reported in the Journal of Clinical Oncology, Mooney et al found that an oncology hospital-at-home program reduced unplanned health-care utilization and costs vs usual care among patients with cancer discharged from the hospital. Study Details In the study, ...
Lustgarten Foundation–AACR Career Development Awards for Pancreatic Cancer Research
Dannielle Engle, PhD, of the Salk Institute for Biological Studies, and Avery D. Posey, PhD, of the Perelman School of Medicine at the University of Pennsylvania, were announced at the American Association for Cancer Research (AACR) Annual Meeting 2021 as the inaugural recipients of the Lustgarten...
A Seasoned Journalist Seeking Answers Reports From the Front Lines of the COVID-19 Pandemic
The COVID-19 pandemic remains a global health issue, putting unprecedented stress on health-care systems, with important implications for cancer care. Although at this stage the data are fairly limited, we know that patients with cancer are far more vulnerable to worse outcomes, including a greater ...
Cancer Has Taught Me to Live With Purpose
I have had two life-threatening cancers over the past 3 decades and can say without equivocation that there is never a good time to get cancer. My first cancer diagnosis happened in 1992, just weeks after I had accepted the position of Chief Executive Officer of Hughes Electronics. The job meant a...
Coagulopathy and COVID-19 Infection
“Life is short, art long, opportunity fleeting, experience treacherous, judgment difficult.” —Hippocrates To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the...
Balancing a Reverence for Life With a Belief That Patients Have a Right to a Dignified Death
The U.S. right-to-die movement took root in the mid-1970s, when Derek Humphry helped his wife, who was dying of breast cancer, take her own life. Five years later, Mr. Humphry founded the Hemlock Society, the first right-to-die organization in the United States,1 and set off a firestorm of...
Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma
On March 26, 2021, idecabtagene vicleucel was approved for the treatment of adults with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.1,2 Idecabtagene vicleucel is...
An Epiphany During Fellowship Led to a Career in Geriatric Oncology for Heidi D. Klepin, MD, MS
Geriatric oncologist Heidi D. Klepin, MD, MS, was born and reared in Pearl River, a hamlet on the west side of the Hudson River in New York. “My parents are German immigrants who came to the United States in the 1960s looking for prospects. Growing up in post-war Germany, neither had the...
American Academy of HIV Medicine Names Leslie McGorman, MPPA, as Director of Public Policy
The American Academy of Human Immunodeficiency Virus (HIV) Medicine recently announced the appointment of Leslie McGorman, MPPA, as its new Director of Public Policy. A seasoned professional in both federal and state government affairs, Ms. McGorman possesses 20 years of health policy experience...
Refining Cardiovascular Risk Assessment in Childhood Cancer Survivors
There are an estimated 500,000 childhood cancer survivors in the United States, a number that will increase exponentially in the coming years. Over half of all childhood cancer survivors will have received cardiotoxic therapies during primary cancer treatment or relapse. For these survivors, there...
Improving Prediction of Risk for 10-Year Left-Ventricular Systolic Dysfunction in Survivors of Childhood Cancer
In a Dutch study reported in JACC: CardioOncology, Jan M. Leerink, PhD candidate, of Amsterdam UMC, University of Amsterdam Department of Clinical and Experimental Cardiology, and colleagues found that the addition of ejection fraction measurement at the time of first surveillance echocardiogram...
Celebrating 50 Years of Cancer Progress: The International View
Although the National Cancer Act of 1971 has resulted in tremendous advances in cancer research, which have led to sharp declines in cancer mortality in the United States—from 1991 to 2018, there has been a 31% decrease in overall cancer death rates—and more than 17 million cancer survivors,1 much...
Nima Sharifi, MD, Receives 2021 AACR–Waun Ki Hong Award in Translational and Clinical Cancer Research
THE AMERICAN ASSOCIATION for Cancer Research (AACR) has recognized Nima Sharifi, MD, with the 2021 AACR–Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research. Dr. Sharifi is Director of the Center for Genitourinary Malignancies Research at Lerner Research...
Ton Schumacher, PhD, FAACR, Receives 2021 AACR-CRI Lloyd J. Old Award in Cancer Immunology
THE AMERICAN ASSOCIATION for Cancer Research (AACR) recognized Ton Schumacher, PhD, FAACR, with the 2021 AACR-CRI Lloyd J. Old Award in Cancer Immunology during the virtual AACR Annual Meeting 2021 in April. The award recognizes an active scientist whose outstanding and innovative research has made ...
First-Line Nivolumab Plus Cabozantinib Improves Progression-Free and Overall Survival vs Sunitinib in Advanced Renal Cell Carcinoma
As reported in The New England Journal of Medicine by Toni K. Choueiri, MD, of Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, and colleagues, the phase III CheckMate 9ER trial has shown that the combination of nivolumab and cabozantinib improved progression-free survival and...
Fam-trastuzumab Deruxtecan-nxki for Trastuzumab-Pretreated Advanced HER2-Positive Gastric Adenocarcinoma
On January 15, 2021, the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki was approved for treatment of adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal adenocarcinoma who have received a prior trastuzumab-based regimen.1,2 Supporting Efficacy Data...
EMPOWER-Lung 1 Trial: New Options, No New Answers
The EMPOWER-Lung 1 trial, recently reported in The Lancet and reviewed in this issue of The ASCO Post, showed an improvement in progression-free and overall survival with cemiplimab-rwlc in patients with advanced non–small cell lung cancer (NSCLC) and high PD-L1 expression (tumor proportion score...
First-Line Cemiplimab-rwlc Improves Outcomes vs Platinum-Doublet Chemotherapy in Advanced NSCLC With PD-L1 Expression ≥ 50%
As reported in The Lancet by Ahmet Sezer, MD, of Başkent University, Adana, Turkey, and colleagues, the phase III EMPOWER-Lung 1 trial has shown improved overall and progression-free survival with cemiplimab-rwlc vs platinum doublet chemotherapy among patients with advanced non–small cell lung...
Inequities in Breast Cancer Screening During the COVID-19 Pandemic
Breast cancer screening took a sizeable hit during the COVID-19 pandemic, according to new research showing that the number of screening mammograms completed in a large group of women living in Washington state plummeted by nearly half. Published by Amram et al in JAMA Network Open, the study...
ASCO Issues Guideline on Dyspnea in Advanced Cancer
ASCO has issued a new guideline on the clinical management of dyspnea in adult patients with advanced cancer.1 Dyspnea—or breathlessness—is a common and distressing symptom affecting upward of 70% of patients with advanced cancer.2 “Dyspnea is a highly prevalent symptom, particularly when people...
ASCO Honors 2021 Special Awards Recipients
Researchers, patient advocates, and global oncology leaders who have worked to reshape cancer care around the world are among the recipients of ASCO’s Special Awards—the Society’s highest honors—and the Women Who Conquer Cancer Mentorship Awards from Conquer Cancer, the ASCO Foundation. “The...
Drive, Curiosity, and a Love of Science: One Nurse’s Road to a Leadership Role in Oncology
For this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Deborah Watkins Bruner, RN, PhD, FAAN, noted for her work in patient-reported outcomes, symptom management, and comparative effectiveness of radiotherapy modalities. Her current research is focused on...
Fluciclovine F-18 PET/CT vs Conventional Imaging Alone in Guiding Postsurgery Salvage Radiotherapy for Prostate Cancer
In a single-institution phase II/III trial (EMPIRE-1) reported in The Lancet, Ashesh B. Jani, MD, and colleagues found that use of fluciclovine F-18 positron-emission tomography/computed tomography (PET/CT) in addition to conventional imaging to guide postprostatectomy salvage radiotherapy was...
Enfortumab Vedotin-ejfv After PD-1 or PD-L1 Inhibitor Therapy for Cisplatin-Ineligible Patients With Advanced Urothelial Carcinoma
As reported in The Lancet Oncology by Evan Y. Yu, MD, and colleagues, findings in a cohort of the phase II EV-201 study showed a high response rate with the nectin-4–directed antibody-drug conjugate enfortumab vedotin-ejfv in cisplatin-ineligible patients with advanced or metastatic urothelial...
Does Long-Term Suppression of Hepatitis B in Patients With HIV Lower Risk of Hepatocellular Carcinoma?
While the risk of hepatocellular carcinoma (HCC) is higher among patients who have human immunodeficiency virus (HIV), it’s even higher among patients who have HIV and detectable hepatitis B, according to research published by Kim et al in Hepatology. Among patients with HIV and hepatitis B,...
Cognitive Performance at Baseline and Over Time in Infants Treated for Brain Tumors
In a prospective longitudinal trial reported in the Journal of Clinical Oncology, Ali et al found that infants treated for central nervous system (CNS) malignancies had baseline intellectual quotient (IQ) and parent-reported working memory and adaptive functioning worse than normative expectations; ...
Machine Learning–Based Algorithm May Predict Short-Term Mortality in Patients With Cancer and Prompt Serious Illness Conversations
Although most patients with terminal cancer, 87%, have end-of-life conversations with clinicians about their goals and preferences for care, on average, these discussions happen just 1 month before death and most often occur in acute care settings with clinicians who are not their treating...
Oral Azacitidine Improves Overall Survival vs Placebo as Maintenance Therapy for AML in First Remission
As reported in The New England Journal of Medicine by Andrew H. Wei, MB, BS, PhD, of the Australian Centre for Blood Diseases, Monash University, Melbourne, and colleagues, the phase III QUAZAR AML-001 trial has shown prolonged overall survival with oral azacitidine maintenance therapy vs placebo...
Pembrolizumab as Long-Term Treatment Option in Relapsed or Refractory Classical Hodgkin Lymphoma
For patients with relapsed or refractory classic Hodgkin lymphoma (HL), salvage chemotherapy followed by autologous hematopoietic stem cell transplant (HSCT) is the standard of care and can induce long-term remissions in at least 60% of patients.1,2 Patients with progression of disease after...
Pembrolizumab Improves Progression-Free Survival vs Brentuximab Vedotin in Relapsed or Refractory Classic Hodgkin Lymphoma
As reported in The Lancet Oncology by John Kuruvilla, MD, of Princess Margaret Cancer Centre, Toronto, and colleagues, an interim analysis of the phase III KEYNOTE-204 trial has shown significantly improved progression-free survival with pembrolizumab vs brentuximab vedotin in patients with...
2021 Genitourinary Cancers Symposium: Advancements in the Care of Older Adults With Prostate Cancer
The 2021 Genitourinary (GU) Cancers Symposium was held in a virtual format on February 11–13 and featured the latest developments in the understanding and treatment of genitourinary cancers. The impact of prostate cancer therapies on outcomes in older adults continues to be a growing area of...
Melphalan Flufenamide for Relapsed or Refractory Multiple Myeloma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On February 26, 2021, the peptide-conjugated alkylating...
NCCN Clinical Practice Guidelines in Oncology: 2021 Updates
In 1996, the National Comprehensive Cancer Network® (NCCN®) published its first set of Clinical Practice Guidelines in Oncology®, covering eight tumor types. Guidelines are now published for more than 60 tumor types and topics. During the NCCN’s 26th Annual Conference, which was held virtually...
Douglas R. Lowy, MD, FAACR, Honored With 2021 AACR–Margaret Foti Award
The American Association for Cancer Research (AACR) presented Douglas R. Lowy, MD, FAACR, with the 2021 AACR–Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research during the virtual AACR Annual Meeting 2021. Dr. Lowy is Chief of the Laboratory of Cellular Oncology,...
FDA Grants Accelerated Approval to Amivantamab-vmjw for Metastatic EGFR Exon 20 Insertion–Mutated NSCLC
On May 21, the U.S. Food and Drug Administration (FDA) granted accelerated approval to amivantamab-vmjw (Rybrevant), a bispecific antibody directed against epidermal growth factor and MET receptors, for adult patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) and...
Expert Point of View: Patrick Y. Wen, MD
“This study is interesting, and the results were a little surprising,” said Patrick Y. Wen, MD, Professor of Neurology at Harvard Medical School and Director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute. “The prognosis of these tumors in children and adolescents is so terrible...
Oncolytic Virotherapy Achieves Early Signs of Success in High-Grade Gliomas
Treatment with genetically engineered oncolytic herpes simplex virus type 1 (HSV-1) G207 alone or with radiation resulted in encouraging outcomes in a small study of pediatric patients with high-grade glioma. In a phase I trial, responses were observed in 11 of 12 children, and median overall...
Expert Point of View: Ezra E.W. Cohen, MD
Formal discussant of the -LIBRETTO-001 trial, Ezra E.W. Cohen, MD, Associate Director for Translational Science and Leader of the Solid Tumor Therapeutics Research Program at the Moores Cancer Center at UC San Diego Health, was encouraged by this trial and said that detection of genetic...
Selpercatinib Makes Inroads in Other RET Fusion–Positive Tumor Types
The selective RET inhibitor selpercatinib is now approved for RET fusion–positive lung and thyroid cancers. New evidence presented at the virtual edition of the American Association for Cancer Research (AACR) Annual Meeting 2021 shows that selpercatinib is active against other RET fusion–positive...
Lisa M. Coussens, PhD, FAACR, Elected AACR President-Elect for 2021–2022
The members of the American Association for Cancer Research (AACR) have elected Lisa M. Coussens, PhD, FAACR, as their President-Elect for 2021–2022. She started her official role as President-Elect on April 12, 2021, during the AACR’s Business Meeting of Members and will assume the Presidency in...
FDA Pipeline: Applications Accepted for Marginal Zone Lymphoma and Lung Cancer
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to zanubrutinib in pretreated patients with marginal zone lymphoma, and accepted a biologics license application for sintilimab injection in combination with pemetrexed and platinum chemotherapy for the first-line...
